Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. Thank you for attending today's VAERS Bioforma first quarter 2025 results conference call. My name is Micaiah and I'll be the moderator for today's call. All lines will be muted in the presentation portion of the call with an opportunity for your questions and answers at the end. At this time, I'd like to pass the call over to our Senior Vice President of Investor Relations and Corporate Communications, Alice Nguye. Alice, you may proceed. Thank you, Micaiah. Good morning, everyone. We appreciate you joining our call this morning. Today, I'm joined by John Shannon, our CEO, and Steve Piper, our CFO. Earlier this morning, we issued a press release with our detailed results, which can be found on our website. After our prepared remarks, we will open the line for questions. Before we begin, I'd like to remind you that this call will contain forward-looking statements concerning the company's future expectations, plans, projects, and financial performance. Forward-looking statements are subject to risks and uncertainties. that could cause actual results to differ materially from those forward-looking statements. For more information on our risks, please refer to our earnings release and risk factors included in our SEC filing. Any forward-looking statements on this call represent our views only as of the date of this call and subject to applicable law. We disclaim any obligations to update such statements. But please note some metrics we will discuss today are presented on a non-GAAP basis. We've reconciled the comparable GAAP and non-GAAP figures in our earnings relief. Let me pass the call over now to John for opening remarks. Thanks, Allison, and good morning, everyone. I'm excited to announce that we're off to an exceptional start this year. In the firs...